RiaSTAP



RiaSTAP

Product Specs RiaSTAP
Manufacturer Name CSL Behring
Indications For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia
Contraindications Anaphylactic or severe reactions to RiaSTAP or its components. Not indicated for dysfibrinogenemia
Viral Safety Process FDA-licensed serological assays, nucleic acid testing
Product Half-Life Adults 82.3 ± 20.0 hours
Children 69.9 ± 8.5 hours
Manufacturing Method Cryoprecipitate into a glycine precipitate, which is then further purified by multiple precipitation/adsorption steps
Storage Requirements
  • Stored at temperatures of 2-8°C (36-46°F)
  • Keep RIASTAP in its original carton until ready to use.
  • Do not freeze.
  • Protect from light.
    		•
    Shelf Life 30 months from manufactured date
    Nominal Vial Size & Diluent Volume 900 mg to 1300 mg/50 mL


    Return to Manufacturer Name listing Return to Factor Type listing